• LAST PRICE
    3.9300
  • TODAY'S CHANGE (%)
    Trending Up0.1500 (3.9683%)
  • Bid / Lots
    3.9200/ 2
  • Ask / Lots
    3.9400/ 5
  • Open / Previous Close
    3.7800 / 3.7800
  • Day Range
    Low 3.7600
    High 3.9400
  • 52 Week Range
    Low 2.5300
    High 16.6500
  • Volume
    23,758
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.78
TimeVolumeATHA
09:32 ET49203.78
09:34 ET25673.805
09:36 ET2003.76
09:38 ET3003.81
09:39 ET14103.83
09:41 ET24193.8699
09:43 ET40003.8819
09:45 ET1003.89
09:48 ET36703.9
09:52 ET19503.93
09:54 ET12003.93
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesATHA
Athira Pharma Inc
142.3M
-2.3x
---
United StatesETNB
89Bio Inc
140.5M
-0.7x
---
United StatesVIRX
Viracta Therapeutics Inc
145.1M
-3.2x
---
United StatesCTXR
Citius Pharmaceuticals Inc
146.1M
-5.0x
---
United StatesINZY
Inozyme Pharma Inc
146.8M
-1.4x
---
United StatesBCAB
Bioatla Inc
147.3M
-1.4x
---
As of 2022-08-08

Company Information

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Contact Information

Headquarters
18706 North Creek Parkway Suite 104, Box 352141BOTHELL, WA, United States 98011
Phone
425-620-8501
Fax
302-636-5454

Executives

Independent Chairwoman of the Board
Kelly Romano
President, Chief Executive Officer, Director
Mark Litton
Chief Financial Officer
Glenna Mileson
Chief Operating Officer
Rachel Lenington
Executive Vice President - Research
Kevin Church

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$142.3M
Revenue (TTM)
$0.00
Shares Outstanding
37.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.72
Book Value
$8.59
P/E Ratio
-2.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.